ESMO26: The “paradigm-shifting” readouts in endometrial & ovarian cancer
At this year’s European Society for Medical Oncology (ESMO) Congress, attention has shifted toward indications that have traditionally received less…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
ESMO26: Key data breathing new life into the lung cancer field
The 2026 European Society for Medical Oncology (ESMO) congress is drawing to a close but has been packed with potentially…
-
AbbVie’s skin disease drug posts Phase III win as market competition heats up
AbbVie’s hidradenitis suppurativa (HS) candidate lutikizumab has demonstrated its potential to significantly reduce flares of the disease, though a the…
-
Roivant eyes Lisraya label expansion on Phase III uveitis win
Roivant and its subsidiary, Priovant Therapeutics, have scored another late-stage win for their marketed ophthalmology therapy, Lisraya (brepocitinib), in non-infectious…
-
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial
Sanofi and Teva Pharmaceuticals’ inflammatory bowel disease (IBD) drug has shown benefit in patients with both ulcerative colitis (UC) and…
-
EyePoint halves workforce and ends Phase III trial early after endpoint miss
EyePoint Pharmaceuticals has announced sweeping job cuts after its eye disease candidate, duravyu, failed to meet its key goal during…
-
Vanda puts anxiety drug’s development on ice after Phase III fail
Vanda Pharmaceuticals has hit pause on a late-stage programme evaluating its small molecule drug, VQW-765, after it failed to demonstrate…
-
MHRA homes in on personalised healthcare and tech in new 2030 strategy
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has devised a new strategy to better harness advancements in personalised…
-
Women’s health landscape shifting, but systemic hurdles remain
It is no secret that research and development (R&D) efforts to improve care in women’s health have long been critically…
-
Mirum tees up Livmarli label expansion on Phase III liver disease study success
Mirum Pharmaceuticals’ marketed therapy, Livmarli (maralixibat), could be poised for a label expansion, after the drug secured a resounding success…